J Rheum Dis 2012; 19(3): 147-151
Published online June 30, 2012
© Korean College of Rheumatology
오일환1ㆍ김진옥1ㆍ변영재1ㆍ성윤경1,2ㆍ최찬범1,2ㆍ김태환1,2ㆍ전재범1,2ㆍ엄완식1,2
한양대학교 의과대학 내과학교실1, 류마티스병원 류마티스내과2
Correspondence to : Wan-Sik Uhm
Behçet's disease (BD) is a multisystemic disorder, which is characterized by recurrent oral aphthous ulcers, genital ulcers, uveitis, and skin lesion. Although intestinal involvement is an uncommon manifestation of the BD, it leads to a poor prognosis, as a result of a high complication, such as intestinal perforation, fistula formation, and massive hemorrhage. Intestinal BD has the tendency for the resistance to conventional medical treatment, and it often requires a surgical intervention because of severe complication. Although the causes of intestinal BD are unknown, some studies show that tumor necrosis factor Alpha (TNF-Ձ) plays a key role in the pathogenesis of BD. Therefore, anti-TNF-Ձ monoclonal antibody, such as adalimumab, is one of the useful treatment for refractory and relapsed intestinal BD. We describe a patient who had intestinal BD complicated enterocutanous fistula with a good response to adalimumab.
Keywords Behçet's disease, Intestine, TNF-Ձ, Adalimumab
J Rheum Dis 2012; 19(3): 147-151
Published online June 30, 2012
Copyright © Korean College of Rheumatology.
오일환1ㆍ김진옥1ㆍ변영재1ㆍ성윤경1,2ㆍ최찬범1,2ㆍ김태환1,2ㆍ전재범1,2ㆍ엄완식1,2
한양대학교 의과대학 내과학교실1, 류마티스병원 류마티스내과2
IL Hwan Oh1, Jin Ok Kim1, Young Jae Byun1, Yoon-Kyoung Sung1,2, Chan-Bum Choi1,2, Tae-Hwan Kim1,2, Jae-Bum Jun1,2, Wan-Sik Uhm1,2
Department of Internal Medicine, Hanyang University College of Medicine1, Department of Rheumatology, Hanyang University Hospital for Rheumatic Disease2, Seoul, Korea
Correspondence to:Wan-Sik Uhm
Behçet's disease (BD) is a multisystemic disorder, which is characterized by recurrent oral aphthous ulcers, genital ulcers, uveitis, and skin lesion. Although intestinal involvement is an uncommon manifestation of the BD, it leads to a poor prognosis, as a result of a high complication, such as intestinal perforation, fistula formation, and massive hemorrhage. Intestinal BD has the tendency for the resistance to conventional medical treatment, and it often requires a surgical intervention because of severe complication. Although the causes of intestinal BD are unknown, some studies show that tumor necrosis factor Alpha (TNF-Ձ) plays a key role in the pathogenesis of BD. Therefore, anti-TNF-Ձ monoclonal antibody, such as adalimumab, is one of the useful treatment for refractory and relapsed intestinal BD. We describe a patient who had intestinal BD complicated enterocutanous fistula with a good response to adalimumab.
Keywords: Behç,et's disease, Intestine, TNF-Ձ,, Adalimumab
Ji Hyoun Kim, M.D., Sang Wan Chung, M.D., Ph.D., Yun Jong Lee, M.D., Ph.D.
J Rheum Dis 2024; 31(3): 178-181Myeung-su Lee, M.D., Ph.D., Chang Hoon Lee, M.D., Ph.D., Hye Soon Lee, M.D., Ph.D., Yoon-Kyoung Sung, M.D., Ph.D., Jung Ran Choi, M.D., Ph.D., Kyungsu Park, M.D., Ph.D., Mi-Kyoung Lim, M.D., Ph.D., Byoong Yong Choi, M.D., Hyoun-Ah Kim, M.D., Ph.D., Seung Won Choi, M.D., Ph.D., Yusun Lee, M.D., Wan-Hee Yoo, M.D., Ph.D.
J Rheum Dis 2021; 28(2): 68-75Eunyoung Ahn, Min Wook So
J Rheum Dis 2018; 25(4): 302-305